19 June 2013
Keywords: gsk, arixtra, cuts, vte, risk, artemis, study
Article | 20 February 2006
UK drug major GlaxoSmithKline says that results from the ARTEMIS study of its antithrombotic Arixtra (fondaparinux sodium) show that it ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
20 February 2006
18 June 2013
© 2013 thepharmaletter.com